Stockscreener 앱 받기
234.20
0.96%
2.12
시간 외 거래:
234.40
0.20
+0.09%
Abbvie Inc 주식(ABBV)의 최신 뉴스
AbbVie Inc. $ABBV Shares Sold by R Squared Ltd - MarketBeat
AbbVie Inc. $ABBV Shares Sold by APG Asset Management N.V. - MarketBeat
Westfield Capital Management Co. LP Takes $1.84 Million Position in AbbVie Inc. $ABBV - MarketBeat
Harvest Portfolios Group Inc. Has $66.12 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Huntington National Bank Purchases 24,310 Shares of AbbVie Inc. $ABBV - MarketBeat
American Century Companies Inc. Cuts Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie (NYSE:ABBV) Shares Up 3.1%Time to Buy? - MarketBeat
AbbVie Executive Sells Over $5 Million in Company Stock - TradingView
AbbVie Inc Stock Closed Up by 3.12% on Feb 27: What Signal Does It Send? - TradingKey
AbbVie Loses Challenge to Contract Pharmacy Law in Tennessee - Bloomberg Law News
AbbVie | 2/27/26 - ktnv.com
One in Three Rheumatologists View BMS’ Sotyktu as a Substantial Advance in Psoriatic Arthritis Ahead of March 6 FDA Decision, According to Spherix Global Insights Data - GlobeNewswire Inc.
AbbVie’s XEN45 Glaucoma Study Signals New Angle in Eye Care Strategy - TipRanks
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term - Nasdaq
Xponance Inc. Grows Holdings in AbbVie Inc. $ABBV - MarketBeat
Generali Investments Management Co LLC Raises Stake in AbbVie Inc. $ABBV - MarketBeat
Handelsbanken Fonder AB Decreases Stake in AbbVie Inc. $ABBV - MarketBeat
Erste Asset Management GmbH Cuts Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AXQ Capital LP Cuts Stake in AbbVie Inc. $ABBV - MarketBeat
Andra AP fonden Grows Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Does AbbVie (ABBV) Share Price Reflect Its DCF Value Despite High P/E Multiple - simplywall.st
GUBRA: Record revenue and profit in 2025, led by AbbVie deal and strong Biotech performance - TradingView
GUBRA: Record earnings from AbbVie deal, strong cash, and major ESG progress define 2025 - TradingView
GUBRA: Record earnings and cash flow in 2025 fueled by AbbVie deal and robust Biotech pipeline - TradingView
AbbVie (ABBV) Announces $7.95 Billion Senior Notes Offering - GuruFocus
AbbVie Announces $7.5 Billion Senior Notes Offering - TipRanks
AbbVie prices $7.95B senior notes offering across maturities to refinance debt - TradingView
Justice Department backs AbbVie in its bid to overturn a Colorado law guiding a drug discount program - statnews.com
Where Will AbbVie Be in 5 Years? - The Globe and Mail
DOJ Supports AbbVie in Suit Over Colorado’s Drug Discount Law - Bloomberg Law News
Thornburg Investment Management Inc. Has $93.02 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
US Bancorp DE Sells 30,755 Shares of AbbVie Inc. $ABBV - MarketBeat
Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie - Seeking Alpha
Intech Investment Management LLC Decreases Holdings in AbbVie Inc. $ABBV - MarketBeat
ABBV SEC FilingsAbbvie Inc 10-K, 10-Q, 8-K Forms - Stock Titan
AbbVie’s CLL Breakthrough And US$380m Build Out Test Valuation - Yahoo Finance
RBC Capital Launches AbbVie (ABBV) Coverage, Expects Shares to Outperform Amid Competitive Fears - Finviz
Here are Wednesday’s top Wall Street analyst research calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and more - MSN
AbbVie Stock Near Highs After Fresh Analyst Calls: Buy The Dip Or Take Profits? - AD HOC NEWS
Key facts: RBC Capital rates AbbVie 'Outperform'; $8B notes offering filed - TradingView
RBC Capital Initiates Coverage of AbbVie (ABBV) with Outperform Recommendation - Nasdaq
RBC Capital Markets Sees Growth Potential for AbbVie (ABBV) - GuruFocus
AbbVie (ABBV) Stock: What RBC’s New Outperform Rating Means for Investors - CoinCentral
AbbVie a new outperform at RBC Capital Markets on durable growth - Seeking Alpha
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent - PharmiWeb.com
RBC Capital Initiates Coverage on AbbVie (ABBV) with Outperform Rating | ABBV Stock News - GuruFocus
Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie - Investing.com Australia
AbbVie’s $100B US deal and FDA reforms highlight growing focus on domestic manufacturing - The Pharma Letter
Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested - Benzinga
AbbVie files for seven-part notes offering of up to $8 billion - marketscreener.com
Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More - 24/7 Wall St.
AbbVie Inc. $ABBV Shares Purchased by MAI Capital Management - MarketBeat
RWA Wealth Partners LLC Has $58.61 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie announces $380m investment in North Chicago API facilities - Pharmaceutical Technology
AbbVie to invest $380 mn in Illinois API facilities - ALCHEMPro
RBC Capital initiates Abbvie stock coverage with outperform rating - Investing.com
AbbVie Tests Exclusion Strategy In Drug Price Fight - Law360
AbbVie joins IG rush to market with US$8bn bond raise - ifr-logo
How Pipeline Shifts And Competition Are Reshaping The AbbVie (ABBV) Investment Narrative - Yahoo Finance
AbbVie makes $380 million ‘made in the U.S.’ move - thestreet.com
Governor Pritzker Announces Major AbbVie Manufacturing Expansion - RiverBender.com
AbbVie to spend $380M on two new manufacturing facilities in Illinois - Manufacturing Dive
Is AbbVie Stock Underperforming the Dow? - Barchart.com
AbbVie Plans to Launch Offering of Senior Notes - marketscreener.com
AbbVie to Present at the TD Cowen 46th Annual Health Care Conference - Investing News Network
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income - Yahoo Finance
AbbVie Inc. (NYSE: ABBV) proposes multi‑series unsecured notes, refinancing $2.0B loan - Stock Titan
AbbVie leaders field investor questions in TD Cowen health care webcast - Stock Titan
FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL - Finviz
0.95%
0.00%
자본화:
|
볼륨(24시간):